Evidence map›Paper›PMID 38918540›Full record

ArticleScientific reports2024

5-fluorouracil and Rumex obtusifolius extract combination trigger A549 cancer cell apoptosis: uncovering PI3K/Akt inhibition by in vitro and in silico approaches.

Mikayel Ginovyan, Hayarpi Javrushyan, Svetlana Hovhannisyan, Edita Nadiryan, Gohar Sevoyan, Tigran Harutyunyan, Smbat Gevorgyan, Zaruhi Karabekian, Alina Maloyan, Nikolay Avtandilyan

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Evaluating the Efficacy of Polyphenol-Enriched Plant Extracts and Pathway Modulators in the Bone Marrow to Suppress Breast Cancer Progression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  5. Article
  6. Article
  7. Food science & nutrition · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mikayel GinovyanResearch Institute of Biology, Yerevan State University, 1 Alex Manoogian, 0025, Yerevan, RA, Armenia.
Hayarpi JavrushyanResearch Institute of Biology, Yerevan State University, 1 Alex Manoogian, 0025, Yerevan, RA, Armenia.
Svetlana HovhannisyanResearch Institute of Biology, Yerevan State University, 1 Alex Manoogian, 0025, Yerevan, RA, Armenia.
Edita NadiryanResearch Institute of Biology, Yerevan State University, 1 Alex Manoogian, 0025, Yerevan, RA, Armenia.
Gohar SevoyanLaboratory of Immunology and Tissue Engineering, L.A. Orbeli Institute of Physiology NAS RA, Yerevan, Armenia.
Tigran HarutyunyanDepartment of Genetics and Cytology, Yerevan State University, Yerevan, Armenia.
Smbat GevorgyanDenovo Sciences Inc, Yerevan, Armenia.
Zaruhi KarabekianLaboratory of Immunology and Tissue Engineering, L.A. Orbeli Institute of Physiology NAS RA, Yerevan, Armenia.
Alina MaloyanCenter for Developmental Health, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, USA.
Nikolay AvtandilyanResearch Institute of Biology, Yerevan State University, 1 Alex Manoogian, 0025, Yerevan, RA, Armenia. nv.avtandilyan@ysu.am.

Funding

Science Committee of MESCS RA 21AG-1F068Science Committee of MESCS RA 21T-1F283Science Committee of MESCS RA 23LCG-1F010
6 · The paper itself

Abstract

The continuous increase in cancer rates, failure of conventional chemotherapies to control the disease, and excessive toxicity of chemotherapies clearly demand alternative approaches. Natural products contain many constituents that can act on various bodily targets to induce pharmacodynamic responses. This study aimed to explore the combined anticancer effects of Rumex obtusifolius (RO) extract and the chemotherapeutic agent 5-fluorouracil (5-FU) on specific molecular targets involved in cancer progression. By focusing on the PI3K/Akt signaling pathway and its related components, such as cytokines, growth factors (TNFa, VEGFa), and enzymes (Arginase, NOS, COX-2, MMP-2), this research sought to elucidate the molecular mechanisms underlying the anticancer effects of RO extract, both independently and in combination with 5-FU, in non-small lung adenocarcinoma A549 cells. The study also investigated the potential interactions of compounds identified by HPLC/MS/MS of RO on PI3K/Akt in the active site pocket through an in silico analysis. The ultimate goal was to identify potent therapeutic combinations that effectively inhibit, prevent or delay cancer development with minimal side effects. The results revealed that the combined treatment of 5-FU and RO demonstrated a significant reduction in TNFa levels, comparable to the effect observed with RO alone. RO modulated the PI3K/Akt pathway, influencing the phosphorylated and total amounts of these proteins during the combined treatment. Notably, COX-2, a key player in inflammatory processes, substantially decreased with the combination treatment. Caspase-3 activity, indicative of apoptosis, increased by 1.8 times in the combined treatment compared to separate treatments. In addition, the in silico analyses explored the binding affinities and interactions of RO's major phytochemicals with intracellular targets, revealing a high affinity for PI3K and Akt. These findings suggest that the combined treatment induces apoptosis in A549 cells by regulating the PI3K/Akt pathway.

Indexed as

ApoptosisFluorouracilPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-aktRumexSignal TransductionA549 CellsComputer SimulationHumansLung NeoplasmsMolecular Docking SimulationFluorouracilPhosphatidylinositol 3-KinasesPlant ExtractsProto-Oncogene Proteins c-akt

Identifiers

PMID38918540
PMCPMC11199614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.